Panbela Therapeutics Long Term Debt 2020-2024 | PBLA

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Panbela Therapeutics long term debt from 2020 to 2024. Long term debt can be defined as the sum of all long term debt fields.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Panbela Therapeutics long term debt from 2020 to 2024. Long term debt can be defined as the sum of all long term debt fields.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$142.2B
Bristol Myers Squibb (BMY)	$117.1B
Gilead Sciences (GILD)	$117.1B
Vertex Pharmaceuticals (VRTX)	$105.1B
CSL (CSLLY)	$85.9B
Regeneron Pharmaceuticals (REGN)	$78.5B
GSK (GSK)	$70.5B
Argenex SE (ARGX)	$38B
Alnylam Pharmaceuticals (ALNY)	$31.4B
BioNTech SE (BNTX)	$27.4B
Biogen (BIIB)	$21.7B
Illumina (ILMN)	$21.4B
BeiGene (BGNE)	$17.7B
Moderna (MRNA)	$15.5B
Genmab (GMAB)	$13.5B
Incyte (INCY)	$13.5B
BioMarin Pharmaceutical (BMRN)	$12.7B
Insmed (INSM)	$12.6B
Sarepta Therapeutics (SRPT)	$11.6B
Bio-Techne Corp (TECH)	$11.6B
Exact Sciences (EXAS)	$10.8B
Vaxcyte (PCVX)	$10.7B
QIAGEN (QGEN)	$10.3B
Swedish Orphan Biovitrum (BIOVF)	$9.8B
Exelixis (EXEL)	$9.7B
Bio-Rad Laboratories (BIO.B)	$9.1B
Intra-Cellular Therapies (ITCI)	$9B
Roivant Sciences (ROIV)	$8.7B
Ascendis Pharma (ASND)	$8.4B
Repligen (RGEN)	$8.2B